Myelodysplastic Syndromes |
From the Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany (UG, CS, SK, AK, RH, NG); Department of Human Genetics, Heinrich-Heine-University, Düsseldorf, Germany (BH); Department of Hematology, Oncology and Clinical Immunology, St. Johannes Hospital, Duisburg, Germany (CA); University of Rochester Medical Center, USA (JMB)
Correspondence: Ulrich Germing, Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Moorenstr. 5, 40225 Düsseldorf, Germany. E-mail: germing{at}med.uni-duessel-dorf.de
The WHO classification moved CMML to myeloproliferative/myelodysplastic disorders, and defined CMML I and CMML II according to medullary and peripheral blast count. To confirm these proposals, we analyzed 266 patients with CMML I and 73 patients with CMML II. Median survival time was 20 months for CMML I, and 15 months for CMML II (p<0.005). The cumulative risk of AML evolution differed between patient groups (p=0.001). No conclusive differences in clinical, morphologic, hematologic or cytogenetic parameters were found. These data support the WHO proposals for the classification of CMML.
Key words: myelodysplastic syndromes, myeloproliferative syndromes, CMML, prognosis, WHO classification.
This article has been cited by other articles:
![]() |
J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood, July 30, 2009; 114(5): 937 - 951. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Suh, T. S. Park, J. S. Kim, J. Song, J. Kim, J.-H. Yoo, and J. R. Choi Chronic Myelomonocytic Leukemia with der(9)t(1;9)(q11;q34) as a Sole Abnormality Ann. Clin. Lab. Sci., January 1, 2009; 39(3): 307 - 312. [Abstract] [Full Text] [PDF] |
||||